Siga Technologies (NASDAQ:SIGA) Releases Earnings Results

Siga Technologies (NASDAQ:SIGA) issued its earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports. Siga Technologies had a negative net margin of 5.19% and a negative return on equity of 1.55%. The company had revenue of $1.32 million during the quarter.

Here are the key takeaways from Siga Technologies’ conference call:

• U.S. procurement timing remains uncertain. SIGA said the process for a new government contract is moving more slowly than in the past, although management continues to believe an award will be made.
• SIGA signed a Canadian TPOXX contract worth up to approximately $15 million. It includes about $9 million in firm commitments over three years, with deliveries expected to begin in 2027, and up to $6 million in options.
• The PEP program’s supplemental NDA filing is now expected in 2028. FDA-requested validation and laboratory work will take additional time, delaying the filing despite SIGA’s continued view that the program is important.
• SIGA reported approximately $42 million in product revenue for the first nine months of 2026, but had no product sales in the third quarter; quarterly net loss was approximately $3 million.
• The company ended the quarter with approximately $116 million in cash and no debt, providing financial capacity amid uncertain government procurement timing.

Siga Technologies Price Performance

SIGA stock opened at $3.26 on Tuesday. The firm has a market cap of $234.23 million, a price-to-earnings ratio of -65.20 and a beta of 1.10. Siga Technologies has a 1-year low of $2.83 and a 1-year high of $7.11. The firm has a fifty day moving average price of $3.19 and a two-hundred day moving average price of $4.30.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Siga Technologies in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Siga Technologies presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SIGA. BlackRock Inc. bought a new stake in shares of Siga Technologies during the 2nd quarter valued at about $15,238,000. Arrowstreet Capital Limited Partnership lifted its holdings in Siga Technologies by 48.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,525,960 shares of the company’s stock worth $8,164,000 after acquiring an additional 500,880 shares during the last quarter. Bank of America Corp DE bought a new position in Siga Technologies in the second quarter worth about $1,555,000. Bank of New York Mellon Corp acquired a new position in Siga Technologies in the second quarter valued at approximately $967,000. Finally, First Wilshire Securities Management Inc. boosted its stake in Siga Technologies by 30.2% in the first quarter. First Wilshire Securities Management Inc. now owns 890,498 shares of the company’s stock valued at $4,764,000 after acquiring an additional 206,445 shares during the period. 55.40% of the stock is owned by institutional investors and hedge funds.

About Siga Technologies

SIGA Technologies, Inc is a commercial-stage pharmaceutical company focused on developing and supplying medical countermeasures for high-consequence infectious diseases. Its primary product is TPOXX (tecovirimat), an antiviral medicine developed to treat smallpox. TPOXX targets orthopoxviruses, the virus family that includes variola virus, which causes smallpox, as well as mpox and other related infections.

TPOXX has been approved by the U.S. Food and Drug Administration in oral and intravenous formulations for the treatment of smallpox.